1. Home
  2. CEG vs VRTX Comparison

CEG vs VRTX Comparison

Compare CEG & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CEG
  • VRTX
  • Stock Information
  • Founded
  • CEG 1999
  • VRTX 1989
  • Country
  • CEG United States
  • VRTX United States
  • Employees
  • CEG N/A
  • VRTX N/A
  • Industry
  • CEG Electric Utilities: Central
  • VRTX EDP Services
  • Sector
  • CEG Utilities
  • VRTX Technology
  • Exchange
  • CEG Nasdaq
  • VRTX Nasdaq
  • Market Cap
  • CEG 108.2B
  • VRTX 115.6B
  • IPO Year
  • CEG N/A
  • VRTX 1991
  • Fundamental
  • Price
  • CEG $322.23
  • VRTX $392.79
  • Analyst Decision
  • CEG Buy
  • VRTX Buy
  • Analyst Count
  • CEG 14
  • VRTX 24
  • Target Price
  • CEG $324.64
  • VRTX $496.76
  • AVG Volume (30 Days)
  • CEG 2.5M
  • VRTX 2.4M
  • Earning Date
  • CEG 08-07-2025
  • VRTX 08-04-2025
  • Dividend Yield
  • CEG 0.48%
  • VRTX N/A
  • EPS Growth
  • CEG 27.80
  • VRTX N/A
  • EPS
  • CEG 9.58
  • VRTX 14.07
  • Revenue
  • CEG $24,820,000,000.00
  • VRTX $11,418,800,000.00
  • Revenue This Year
  • CEG $0.18
  • VRTX $10.40
  • Revenue Next Year
  • CEG $3.55
  • VRTX $10.63
  • P/E Ratio
  • CEG $33.65
  • VRTX $27.92
  • Revenue Growth
  • CEG 5.42
  • VRTX 10.46
  • 52 Week Low
  • CEG $161.35
  • VRTX $362.50
  • 52 Week High
  • CEG $357.00
  • VRTX $519.88
  • Technical
  • Relative Strength Index (RSI)
  • CEG 45.99
  • VRTX 38.39
  • Support Level
  • CEG $322.50
  • VRTX $362.50
  • Resistance Level
  • CEG $342.75
  • VRTX $396.72
  • Average True Range (ATR)
  • CEG 13.10
  • VRTX 14.18
  • MACD
  • CEG -2.79
  • VRTX -4.22
  • Stochastic Oscillator
  • CEG 6.83
  • VRTX 26.98

About CEG Constellation Energy Corporation

Constellation Energy Corp producer of carbon-free energy and a supplier of energy products and services. The company offers generating capacity that includes nuclear, wind, solar, natural gas, and hydroelectric assets. It sells electricity, natural gas, and other energy-related products and sustainable solutions to various types of customers, including distribution utilities, municipalities, cooperatives, and commercial, industrial, public sector, and residential customers in markets across multiple geographic regions. Its operating segments and reporting units are Mid-Atlantic, Midwest, New York, ERCOT, and Other Power Regions.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: